Osteologie 2011; 20(04): 7-8
DOI: 10.1055/s-0037-1620018
Vitamin D
Schattauer GmbH

Literatur

B. Mentrup
Further Information

Publication History

Publication Date:
30 December 2017 (online)

 

 
  • Literatur

  • 1 Amling M, Priemel M, Holzmann T. et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999; 140: 4982-4987.
  • 2 Barsony J, Prufer K. Vitamin D receptor and retinoid X receptor interactions in motion. Vitam Horm 2002; 65: 345-376.
  • 3 Bell TD, Demay MB, Burnett-Bowie SA. The biology and pathology of vitamin D control in bone. J Cell Biochem 2010; 111: 7-13.
  • 4 Bikle DD. Vitamin D metabolism and function in the skin. Mol Cell Endocrinol. 2011 Jun 1. [Epub ahead of print].
  • 5 Bikle DD. Vitamin D: an ancient hormone. Exp Dermatol 2011; 20: 7-13.
  • 6 Biswas P, Zanello LP. 1alpha,25(OH)(2) vitamin D(3) induction of ATP secretion in osteoblasts. J Bone Miner Res 2009; 24: 1450-1460.
  • 7 Boland RL. VDR activation of intracellular signaling pathways in skeletal muscle. Mol Cell Endocrinol. 2011 Jun 1. [Epub ahead of print].
  • 8 Campbell FC, Xu H, El-Tanani M. et al. The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol 2010; 79: 1-9.
  • 9 Carlberg C, Seuter S. Dynamics of nuclear receptor target gene regulation. Chromosoma 2010; 119: 479-484.
  • 10 Chen J, Olivares-Navarrete R, Wang Y. et al. Proteindisulfide isomerase-associated 3 (Pdia3) mediates the membrane response to 1,25-dihydroxyvitamin D3 in osteoblasts. J Biol Chem 2010; 285: 37041-37050.
  • 11 Chen Q, Zhang T, Wang JF, Wei DQ. Advances in human cytochrome p450 and personalized medicine. Curr Drug Metab 2011; 12: 436-444.
  • 12 Christakos S, Deluca HF. Minireview: Vitamin D: Is There a Role in Extraskeletal Health?. Endocrinology. 2011 June 14. [Epub ahead of print].
  • 13 Christakos S, Dhawan P, Ajibade D. et al. Mechanisms involved in vitamin D mediated intestinal calcium absorption and in non-classical actions of vitamin D. J Steroid Biochem Mol Biol 2010; 121: 183-187.
  • 14 Dirks-Naylor AJ, Lennon-Edwards S. The effects of vitamin D on skeletal muscle function and cellular signaling. J Steroid Biochem Mol Biol 2011; 125: 159-168.
  • 15 Dusso AS, Thadhani R, Slatopolsky E. Vitamin D receptor and analogs. Semin Nephrol 2004; 24: 10-16.
  • 16 Ebert R, Schutze N, Adamski J, Jakob F. Vitamin D signaling is modulated on multiple levels in health and disease. Mol Cell Endocrinol 2006; 248: 149-159.
  • 17 Fang Y, Rivadeneira F, van Meurs JB. et al. Vitamin D receptor gene BsmI and TaqI polymorphisms and fracture risk: a meta-analysis. Bone 2006; 39: 938-945.
  • 18 Gonzalez-Sancho JM, Larriba MJ. Ordonez-Moran et al. Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Anticancer Res 2006; 26: 2669-2681.
  • 19 Gynther P, Toropainen S, Matilainen JM. et al. Mechanism of 1alpha,25-dihydroxyvitamin D(3)-dependent repression of interleukin-12B. Biochim Biophys Acta 2011; 1813: 810-818.
  • 20 Hewison M. Vitamin D and innate and adaptive immunity. Vitam Horm 2011; 86: 23-62.
  • 21 Holick MF. Vitamin D: evolutionary, physiological and health perspectives. Curr Drug Targets 2011; 12: 4-18.
  • 22 Huldschinsky K. Heilung von Rachitis durch künstliche Höhensonne. Deutsche Medizinische Wochenschrift 1919; 45: 712-713.
  • 23 Jakob F, Gieseler F, Tresch A. et al. Kinetics of nuclear translocation and turnover of the vitamin D receptor in human HL60 leukemia cells and peripheral blood lymphocytes--coincident rise of DNA-relaxing activity in nuclear extracts. J Steroid Biochem Mol Biol 1992; 42: 11-16.
  • 24 Jakob F, Seufert J, Sarrazin C. et al. Topoisomerase I-inhibition enhances vitamin D-responsive expression of the receptor for lipopolysaccharide binding protein CD 14. Biochem Biophys Res Commun 1994; 199: 531-539.
  • 25 Jakob F, Ebert R, Seefried L. et al. Laboruntersuchungen bei metabolischen Osteopathien – Rachitis und Osteomalazie, Hypophosphatasie, M. Paget. Osteologie 2009; 18: 16-23.
  • 26 Kato S, Fujiki R. Transcriptional controls by nuclear fat-soluble vitamin receptors through chromatin reorganization. Biosci Biotechnol Biochem 2011; 75: 410-413.
  • 27 Keisala T, Minasyan A, Lou YR. et al. Premature aging in vitamin D receptor mutant mice. J Steroid Biochem Mol Biol 2009; 115: 91-97.
  • 28 Krasowski MD, Ni A, Hagey LR, Ekins S. Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol Cell Endocrinol 2011; 334: 39-48.
  • 29 Kriebitzsch C, Verlinden L, Eelen G. et al. The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells--a microarray approach. Anticancer Res 2009; 29: 3471-3483.
  • 30 Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol 2011; 22: 216-224.
  • 31 Lisse TS, Hewison M, Adams JS. Hormone response element binding proteins: novel regulators of vitamin D and estrogen signaling. Steroids 2011; 76: 331-339.
  • 32 Lou YR, Molnar F, Perakyla M. et al. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J Steroid Biochem Mol Biol 2010; 118: 162-170.
  • 33 Luderer HF, Demay MB. The vitamin D receptor, the skin and stem cells. J Steroid Biochem Mol Biol 2010; 121: 314-316.
  • 34 MacDonald PN, Dowd DR, Zhang C, Gu C. Emerging insights into the coactivator role of NCoA62/SKIP in Vitamin D-mediated transcription. J Steroid Biochem Mol Biol. 2004 89–90, 179–186.
  • 35 Marik R, Fackler M, Gabrielson E. et al. DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biol Ther 2010; 10: 44-53.
  • 36 Markov GV, Laudet V. Origin and evolution of the ligand-binding ability of nuclear receptors. Mol Cell Endocrinol 2011; 334: 21-30.
  • 37 Masuda S, Jones G. Vitamin D analogs – drug design based on proteins involved in vitamin D signal transduction. Curr Drug Targets Immune Endocr Metabol Disord 2003; 03: 43-66.
  • 38 Mathew S, Lund RJ, Chaudhary LR. et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19: 1509-1519.
  • 39 Maund SL, Barclay WW, Hover LD. et al. Interleukin-1 alpha mediates the anti-proliferative effects of 1,25 dihydroxyvitamin D3 in prostate progenitor/ stem cells. Cancer Res 2011; 71 (15) 5276-5286.
  • 40 McDonnell DP, Mangelsdorf DJ, Pike JW. et al. Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science 1987; 235: 1214-1217.
  • 41 Messa P, Alfieri C, Rastaldi MP. Recent insights into vitamin D and its receptor. J Nephrol 2011; 24 (Suppl. 18) S30-S37.
  • 42 Nemere I, Garbi N, Hammerling GJ, Khanal RC. Intestinal cell calcium uptake and the targeted knockout of the 1,25D3-MARRS (membrane-associated, rapid response steroid-binding) receptor/ PDIA3/Erp57. J Biol Chem 2010; 285: 31859-31866.
  • 43 Ordonez-Moran P, Munoz A. Nuclear receptors: genomic and non-genomic effects converge. Cell Cycle 2009; 08: 1675-1680.
  • 44 Perez E, Bourguet W, Gronemeyer H, de Lera AR. Modulation of RXR function through ligand design. Biochim Biophys Acta. 2011 April 16. [Epub ahead of print].
  • 45 Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987; 330: 444-450.
  • 46 Piek E, Sleumer LS, van Someren EP. et al. Osteotranscriptomics of human mesenchymal stem cells: accelerated gene expression and osteoblast differentiation induced by vitamin D reveals c-MYC as an enhancer of BMP2-induced osteogenesis. Bone 2010; 46: 613-627.
  • 47 Pike JW. Emerging concepts on the biologic role and mechanism of action of 1,25-dihydroxyvitamin D3. Steroids 1987; 49: 3-27.
  • 48 Pike JW. Genome-wide principles of gene regulation by the vitamin D receptor and its activating ligand. Mol Cell Endocrinol. 2011 Jun 1. [Epub ahead of print].
  • 49 Pike JW, Meyer MB, Martowicz ML. et al. Emerging regulatory paradigms for control of gene expression by 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 2010; 121: 130-135.
  • 50 Pritchard E. The Causation and Treatment of Rickets. Br Med J 1919; 02: 627-629.
  • 51 Quack M, Carlberg C. Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs. Mol Pharmacol 1999; 55: 1077-1087.
  • 52 Richard CL, Farach-Carson MC, Rohe B. et al. Involvement of 1,25D3-MARRS (membrane associated, rapid response steroid-binding), a novel vitamin D receptor, in growth inhibition of breast cancer cells. Exp Cell Res 2010; 316: 695-703.
  • 53 Richards JB, Kavvoura FK, Rivadeneira F. et al. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med 2009; 151: 528-537.
  • 54 Sakaki T, Sugimoto H, Hayashi K. et al. Bioconversion of vitamin D to its active form by bacterial or mammalian cytochrome P450. Biochim Biophys Acta 2011; 1814: 249-256.
  • 55 Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 2011; 1814: 186-199.
  • 56 Schutze N, Bachthaler M, Lechner A. et al. Identification by differential display PCR of the selenoprotein thioredoxin reductase as a 1 alpha,25(OH)2-vitamin D3-responsive gene in human osteoblasts – regulation by selenite. Biofactors 1998; 07 (04) 299-310.
  • 57 Schutze N, Fritsche J, Ebert-Dumig R. et al. The selenoprotein thioredoxin reductase is expressed in peripheral blood monocytes and THP1 human myeloid leukemia cells--regulation by 1,25-dihydroxyvitamin D3 and selenite. Biofactors 1999; 10: 329-338.
  • 58 Schutze N, Lechner A, Groll C. et al. The human analog of murine cystein rich protein 61 [correction of 16] is a 1alpha,25-dihydroxyvitamin D3 responsive immediate early gene in human fetal osteoblasts: regulation by cytokines, growth factors, and serum. Endocrinology 1998; 139: 1761-1770.
  • 59 Sierralta WD, Bortsch AC, Gaues J. et al. Estradiolpromoted accumulation of receptor in nuclei of porcine endometrium cells. Comparison of the retention of receptor in nuclei during subcellular fractionation of untreated and hormone-treated cells. Receptor 1992; 02: 17-28.
  • 60 Sierralta WD, Jakob F, Thole H. et al. Estradiol-promoted accumulation of receptor in nuclei of porcine endometrium cells. Immunogold electron microscopy of resting and estradiol-stimulated cells. Receptor 1992; 02: 29-37.
  • 61 Sooy K, Sabbagh Y, Demay MB. Osteoblasts lacking the vitamin D receptor display enhanced osteogenic potential in vitro. J Cell Biochem 2005; 94: 81-87.
  • 62 Sundar IK, Hwang JW, Wu S. et al. Deletion of vitamin D receptor leads to premature emphysema/ COPD by increased matrix metalloproteinases and lymphoid aggregates formation. Biochem Biophys Res Commun 2011; 406: 127-133.
  • 63 Takeyama K, Kato S. The vitamin D3 1alpha-hydroxylase gene and its regulation by active vitamin D3. Biosci Biotechnol Biochem 2011; 75: 208-213.
  • 64 Uitterlinden AG, Ralston SH, Brandi ML. et al. The association between common vitamin D receptor gene variations and osteoporosis: a participantlevel meta-analysis. Ann Intern Med 2006; 145: 255-264.
  • 65 van Leeuwen JP, van Driel M, van den Bemd GJ, Pols HA. Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit Rev Eukaryot Gene Expr 2001; 11: 199-226.
  • 66 Vanoirbeek E, Eelen G, Verlinden L. et al. Microarray analysis of MCF-7 breast cancer cells treated with 1,25-dihydroxyvitamin D3 or a 17-methyl-D-ring analog. Anticancer Res 2009; 29: 3585-3590.
  • 67 Wali RK, Kong J, Sitrin MD. et al. Vitamin D receptor is not required for the rapid actions of 1,25-dihydroxyvitamin D3 to increase intracellular calcium and activate protein kinase C in mouse osteoblasts. J Cell Biochem 2003; 88: 794-801.
  • 68 Wang WL, Chatterjee N, Chittur SV. et al. Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer 2011; 10: 58.
  • 69 Welsh J, Zinser LN, Mianecki-Morton L. et al. Agerelated changes in the epithelial and stromal compartments of the mammary gland in normocalcemic mice lacking the vitamin D3 receptor. PLoS One 2011; 06: e16479.
  • 70 Wu W, Beilhartz G, Roy Y. et al. Nuclear translocation of the 1,25D3-MARRS (membrane associated rapid response to steroids) receptor protein and NFkappaB in differentiating NB4 leukemia cells. Exp Cell Res 2010; 316: 1101-1108.
  • 71 Zanatta L, Zamoner A, Zanatta AP. et al. Nongenomic and genomic effects of 1alpha,25(OH)(2) vitamin D(3) in rat testis. Life Sci. 2011 89. (15–16): 515–523. Epub 2011 Apr 30.
  • 72 Zanello LP, Norman AW. Rapid modulation of osteoblast ion channel responses by 1alpha,25(OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor. Proc Natl Acad Sci U S A 2004; 101: 1589-1594.